# A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

> **NCT06223360** · PHASE2 · RECRUITING · sponsor: **Alzheimer's Disease Cooperative Study (ADCS)** · enrollment: 406 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Low Dose Benfotiamine
- **DRUG:** High Dose Benfotiamine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06223360
- **Lead sponsor:** Alzheimer's Disease Cooperative Study (ADCS)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-28
- **Primary completion:** 2027-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 406 (ESTIMATED)
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06223360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06223360, "A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06223360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*